HuGE Literature Finder
Records 1-6
|
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Molecular cancer 2018 Feb 17 (1): 67. Takeshita Takashi, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Tomiguchi Mai, Sueta Aiko, Murakami Keiichi, Iwase Hirota |
|
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
BMC cancer 2016 Nov 16 (1): 864. Ko Ryo, Kenmotsu Hirotsugu, Serizawa Masakuni, Koh Yasuhiro, Wakuda Kazushige, Ono Akira, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Isaka Mitsuhiro, Endo Masahiro, Nakajima Takashi, Ohde Yasuhisa, Yamamoto Nobuyuki, Takahashi Kazuhisa, Takahashi Toshia |
|
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
Cancer 2016 Sep . Makker Vicky, Recio Fernando O, Ma Ling, Matulonis Ursula A, Lauchle Jennifer O, Parmar Hema, Gilbert Houston N, Ware Joseph A, Zhu Rui, Lu Shan, Huw Ling-Yuh, Wang Yulei, Koeppen Hartmut, Spoerke Jill M, Lackner Mark R, Aghajanian Carol |
|
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Asian Pacific journal of cancer prevention : APJCP 2012 13 (5): 2157-62. Xu Jia-Li, Wang Zhen-Wu, Hu Ling-Min, Yin Zhi-Qiang, Huang Ming-De, Hu Zhi-Bin, Shen Hong-Bing, Shu Yong-Qi |
|
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): 3530. Oliner K, Peeters M, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem J, Andre T, Wiezorek J S, Patterson S |
|
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2011 Jan 71 (1): 82-8. Pu Xia, Hildebrandt Michelle A T, Lu Charles, Lin Jie, Stewart David J, Ye Yuanqing, Gu Jian, Spitz Margaret R, Wu Xife |
- Page last reviewed:Oct 1, 2020
- Page last updated:Nov 27, 2020
- Content source: